<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MEXILETINE</span><br/>(mex-il'e-teen)<br/><span class="topboxtradename">Mexitil<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">antiarrhythmic, class ib</span><br/><b>Prototype: </b>Lidocaine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>150 mg, 200 mg, 250 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Analog of lidocaine with class IB electrophysiologic properties similar to those of procainamide. Shortens action potential
         refractory period duration and improves resting potential.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Has little or no effect on atrial tissue and produces modest suppression of sinus node automatically and AV nodal conduction.
         Prolongs the His-to-ventricular interval (HQ) only if patient has preexisting conduction disturbance.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Acute and chronic ventricular arrhythmias; prevention of recurrent cardiac arrests; suppression of PVCs due to ventricular
         tachyarrhythmias.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Wolff-Parkinson-White syndrome and supraventricular arrhythmias.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Severe left ventricular failure, cardiogenic shock, severe bradyarrhythmias. Preexisting second- or third-degree heart block;
         pregnancy (category C), lactation; concurrent administration of drugs which alter urinary pH.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients with sinus node conduction irregularities, intraventricular conduction abnormalities; hypotension; severe congestive
         heart failure; liver dysfunction.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Ventricular Arrhythmias</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200300 mg q8h (max: 1200 mg/d)<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 1.45 mg/kg q8h<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food or milk to reduce gastric distress.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Dizziness, tremor, nervousness, incoordination,</span> headache, blurred vision, paresthesias, numbness. <span class="typehead">CV:</span>
<span class="speceff-life">Exacerbated arrhythmias</span>, palpitations, chest pain, syncope, hypotension. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, heartburn,</span> diarrhea, constipation, dry mouth, abdominal pain. <span class="typehead">Skin:</span> Rash. <span class="typehead">Body as a Whole:</span> Dyspnea, edema, arthralgia, fever, malaise, hiccups. <span class="typehead">Urogenital:</span> Impotence, urinary retention. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Phenytoin,</b>
<b>phenobarbital,</b>
<b>rifampin</b> may decrease mexiletine levels; <b>cimetidine,</b>
<b>fluvoxamine</b> may increase mexiletine levels; may increase <b>theophylline</b> levels; may increase proarrhythmic effects of <b>dofetilide</b> (separate administration by at least 1 wk). 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 23 h. <span class="typehead">Distribution:</span> Distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine; renal elimination increases with urinary acidification. <span class="typehead">Half-Life:</span> 1012 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Check pulse and BP before administration; make sure both are stabilized.</li>
<li>Effective serum concentration range is 0.52 mcg/mL.</li>
<li>Lab tests: Baseline and periodic liver function tests.</li>
<li>Supervise ambulation in the weak, debilitated patient or the older adult during drug stabilization period. CNS adverse reactions
            predominate (e.g., intention tremors, nystagmus, blurred vision, dizziness, ataxia, confusion, nausea).
         </li>
<li>Encourage drug compliance; affected particularly by the distressing adverse effects of tremor, ataxia, and eye symptoms.</li>
<li>Check frequently with patient about adherence to drug regimen. If adverse effects are increasing, consult physician. Dose
            adjustment or discontinuation may be needed.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn about pulse parameters to be reported: Changes in rhythm and rate (bradycardia = pulse below 60); symptomatic bradycardia
            (light-headedness, syncope, dizziness), and postural hypotension.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>